Blueprint Medicines Corp (BPMC)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$90.47
Buy
$90.59
$-0.24 (-0.26%)
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.
Prices updated at 27 Mar 2025, 19:35 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
| Year | Gross margin (%) | Operating margin (%) | Net margin (%) | EBITDA margin (%) | EBITDA |
|---|---|---|---|---|---|
| 2024 | 96.04 | -41.67 | -13.19 | 3.78 | 19m |
| 2023 | 96.58 | -193.29 | -203.30 | -177.54 | -443m |
| 2022 | 91.27 | -259.06 | -273.24 | -253.31 | -517m |
| 2021 | 90.04 | -352.17 | -357.67 | -348.57 | -628m |
| 2020 | 99.95 | 38.89 | 39.54 | 39.72 | 315m |
| 2019 | 100.00 | -543.25 | -522.75 | -535.34 | -356m |
| 2018 | 100.00 | -554.86 | -531.53 | -545.32 | -243m |
| 2017 | - | -705.90 | -691.30 | -698.54 | -150m |
| 2016 | - | -261.33 | -261.04 | -253.65 | -70m |
Valuation data table
| Year | Price / Sales | Price earnings | Price / Cash flow |
|---|---|---|---|
| 2025 | 11.21 | - | - |
| 2024 | 12.48 | - | - |
| 2023 | 25.73 | - | - |
| 2022 | 9.56 | - | - |
| 2021 | 58.29 | - | - |
| 2020 | 7.46 | 19.11 | 16.48 |
| 2019 | 232.74 | - | - |
| 2018 | 51.23 | - | - |
| 2017 | 95.75 | - | - |
| 2016 | 30.80 | - | - |
| 2015 | - | - | - |
Price/Forward earnings (YTD)
-86.96
Returns
Debt profile
Returns data table
| Year | Return on assets (%) | Return on equity (%) | Return on invested capital (%) |
|---|---|---|---|
| 2024 | -6.02 | -31.26 | -7.29 |
| 2023 | -42.26 | -157.13 | -80.66 |
| 2022 | -42.85 | -75.07 | -60.62 |
| 2021 | -43.36 | -52.78 | -48.76 |
| 2020 | 25.88 | 32.45 | 29.61 |
| 2019 | -55.73 | -78.72 | -69.96 |
| 2018 | -37.69 | -45.38 | -44.01 |
| 2017 | -29.67 | -35.39 | -34.35 |
| 2016 | -31.40 | -40.61 | -38.33 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 3.95 |
| 2023 | 8.03 |
| 2022 | 2.62 |
| 2021 | 1.29 |
| 2020 | 1.17 |
| 2019 | 1.52 |
| 2018 | 1.29 |
| 2017 | 1.15 |
| 2016 | 1.33 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
